Background: Primary effusion lymphoma (PEL) is a Kaposi's sarcoma herpes virus (KSHV)-induced lymphoma that typically arises in body cavities of HIV-infected patients. PEL cells are often co-infected with Epstein-Barr virus (EBV). "PEL-like" lymphoma is a KSHV-unrelated lymphoma that arises in body cavities of HIV-negative patients. "PEL-like" lymphoma is sometimes EBV positive. The derivation of PEL/"PEL-like" cells is unclear. Methods: Mesothelial cells were cultured from body cavity effusions of 23 patients. Cell proliferation, cytokine secretion, marker phenotypes, KSHV/EBV infection, and clonality were evaluated by standard methods. Gene expression was measured by quantitative polymerase chain reaction and immunoblotting. A mouse model of PEL (3 mice/group) was used to evaluate tumorigenicity. Results: We found that the mesothelia derived from six effusions of HIV-infected patients with PEL or other KSHV-associated diseases contained rare KSHV þ or EBV þ mesothelial cells. After extended culture (16-17 weeks), some mesothelial cells under-
went a trans-differentiation process, generating lymphoid-type CD45
, and CD3 À cells resembling "B1-cells," most commonly found in mouse body cavities. These "B1-like" cells were short lived. However, longterm KSHV þ EBV À and EBV þ KSHV À clonal cell lines emerged from mesothelial cultures from two patients that were clonally distinct from the monoclonal or polyclonal B-cell populations found in the patients' original effusions.
Conclusions: Mesothelial-to-lymphoid transformation is a newly identified in vitro process that generates "B1-like" cells and is associated with the emergence of long-lived KSHV or EBV-infected cell lines in KSHV-infected patients. These results identify mesothelial cultures as a source of PEL cells and lymphoid cells in humans.
Primary effusion lymphoma (PEL) is a malignancy that predominantly arises in HIV-infected patients. PEL was first recognized as a distinct clinical entity in patients with AIDS based on its unusual presentation as a liquid malignancy generally confined to body cavities, the "indeterminate" phenotype of the tumor cells (1) , and the presence of Kaposi's sarcoma herpes virus (KSHV) in the tumor cells, with or without Epstein-Barr virus (EBV) (2) . KSHV þ PEL cells are of B-cell lineage as they display Ig gene rearrangements, the common leukocyte antigen CD45 (2) , and the plasmablast/plasma cell marker CD138 in some cases (3) but usually lack surface and cytoplasmic Ig and the mature B-cell markers CD19 and CD20 (4) . KSHV is also associated with Kaposi's sarcoma (KS), plasmablastic multicentric Castleman disease (KSHV-MCD), and a KSHV-associated inflammatory cytokine syndrome (KICS). Patients with KS, KICS, and KSHV-MCD may develop recurrent pleural effusions of unclear etiology (5) . KSHV-unrelated "PEL-like" lymphomas anatomically confined to body cavities constitute a distinct entity (6, 7) . These PEL-like lymphomas have a mature B-cell phenotype with CD19 and CD20 expression, tend to occur in elderly patients, and often have a favorable prognosis (6, 7) . A proportion of "PEL-like" lymphomas are EBV positive (7) .
The body cavity site of PEL and PEL-like lymphomas suggested that this microenvironment contributes to their development and/or progression. To gain insight into this process, we focused on the mesothelium that lines these cavities (8) . Here, we have examined potential mechanisms by which the mesothelium may contribute to the emergence and progression of PEL and PEL-like lymphomas.
Methods

Patients
HIV
þ patients with KSHV-related diseases (17 patients) ( Table 1) and patients with ovarian carcinoma (six patients) at the Clinical Center, National Cancer Institute (NCI), Bethesda, Maryland, provided biospecimens. PEL, KS, and KSHV-MCD diagnoses were confirmed pathologically. KICS diagnosis was based on a working definition (9 
Cells and Proliferation
Primary cultures of mesothelial cells were established from effusions (detailed in the Supplementary Methods, available on line). The PEL cell lines BC-1, BC-3, and BCBL-1 were cultured as described (10) (11) (12) . Cell proliferation was measured by 3 H-thymidine incorporation as described (13) . Population doublings were calculated from viable cell counting as log 2 (C t /C o ), where C o was number cells seeded and C t was number cells harvested; mesothelial cells when confluent status was first achieved were considered population doubling at 0.
Gene Expression and Clonality
Lentivirus for Azurite expression was generated in 293T cells (American Type Culture Collection) Manassas, VA, USA by transfection of the pLV-Azurite short hairpin RNA construct (Addgene, 36086) Cambridge, MA, USA and third-generation packaging plasmids (pMDLg/pRRE; pRSV-Rev and a VSVG envelop), as described (14) . RNA was purified, and cDNA was synthesized as described (14) . Quantitative polymerase chain reaction (qPCR) was performed as described in Supplementary Methods (available online) using the primers listed in Supplementary Table 1 (available online) . B-cell clonality and immunoglobulin gene rearrangements were evaluated as described (15, 16) and detailed in the Supplementary Methods (available online).
KSHV and EBV Sequencing
KSHV-K1 and EBV B95-8-deleted region were sequenced (17, 18) and comparative sequence analysis performed as described (19) and detailed in Supplementary Methods (available online).
Immunoblotting and Immunofluorescence
Immunoblotting was performed as described in the Supplementary Methods (available online). Immunostaining is detailed in the Supplementary Methods (available online), with primary and secondary antibodies listed in Supplementary  Table 2 (available online) .
Mouse Model
The animal protocol (20) was approved by the Institutional Animal Care and Use Committee of the Center for Cancer Research, NCI, National Institutes of Health (NIH) (Bethesda, MD); the studies were conducted in adherence to the NIH Guide for Care and Use of Laboratory Animals. Groups of female NOD/ SCID mice (three mice/group; six weeks old) were injected intraperitoneally (i.p.) with lymphoid cell lines emerging from mesothelial cultures (5x10 6 cells/mouse in 0.2 mL PBS) or with the PEL cell line BC-1 (10x10 6 cells/mouse in 0.2 mL PBS) as described (12) . The mice were observed until evidence of excessive abdominal distension interfering with mouse motility or causing distress emerged, at which time the mice were killed and evaluated for evidence of ascites and intraperitoneal tumor.
Statistical Analysis
The standard deviation and standard error of the mean (SEM) were calculated by standard methods; the statistical significance of differences between two groups was calculated by two-tailed Student's t test, where P values of less than .05 are considered statistically significant.
Results
Isolation of Mesothelial Cell Monolayers From Effusions
Pleural or peritoneal effusions from HIV-infected patients with PEL (henceforth called "PEL-effusions"; n ¼ 6); HIV-associated KS, KSHV-MCD, and/or KICS without PEL (henceforth called "KSHV-effusions"; n ¼ 11); and ovarian cancer (n ¼ 6) ( Table 1 ) generated typical cobblestone-like mesothelial monolayers (21) (Supplementary Figure 1A , available online). Cells within these monolayers were uniformly Vimentin Figure 1B , available online), consistent with a mesothelial identity (22) . Similar to omentum-derived human mesothelial cells (23) , effusion-derived mesothelial cells reached confluency within five to seven days during initial (1-4) passages, and this proliferative capacity declined after seven to 14 passages, particularly in mesothelial cultures from ovarian carcinoma patients, attributable perhaps to chemotherapy-induced mesothelial toxicity ( Figure 1A ) (23) .
When cytokines were evaluated in conditioned media of mesothelial cultures (at week 3 or 4), IL-6 was unique as it was detected at statistically significantly higher levels in culture supernatants from PEL (P ¼ .02) and KSHV (P ¼ .03) effusions compared with cultures from ovarian cancer effusions 
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( Figure 1B ). The opposite was true for VEGF-A, IFNc, IP-10, and IL6 receptor (R). Most of the remainder cytokines were present at similar levels in the three groups. It was previously shown that PEL cells proliferate in response to IL-10 and IL-6 (20, 24) . We found that PEL cell lines BC-1, BCBL-1, and primary PEL cells proliferated better in the presence of mesothelial monolayers from PEL and KSHV effusions than in their absence (BC-1: P ¼ .01 and P ¼ .02, respectively; BCBL-1: P ¼ .01 and P ¼ .02, respectively; primary PEL: P ¼ .005 and P ¼ .003, respectively) ( Figure 1C ). This shows that mesothelial monolayers support PEL cell growth, attributable perhaps to the biologically active IL-10 and IL-6 they produce.
By immunoblotting, HIV þ patient-derived mesothelial cell lysates from passage 3 or 4 lacked the viral protein latencyassociated nuclear antigen (LANA)-1, which marks KSHV infection (Supplementary Figure 1C , available online). In two cases, we could test lysates from fresh PEL cells and mesothelium from the same effusion; LANA-1 was detected in PEL but not in the mesothelium (Supplementary Figure 1C , available online).
Emergence of Lymphoid "B1-Type" Cells From Mesothelium
We monitored mesothelial cell cultures beyond the proliferative stage into "senescence" (23), characterized by enlarged/flattened cells with vacuolated nuclei and loss of monolayer integrity ( Figure 2A) . Initially rare, round cells with lymphoid morphology appeared within the adherent monolayer, which retained mesothelial morphology with some evidence of "senescence" ( [29, 30, 34, 35] ). Only subsets of cells displayed the B-lineage markers CD19 and CD20. Tcell markers, including CD3; the myeloid-lineage markers CD11b and CD68; and surface IgD were generally absent. Mesothelial cultures initially produced little IgM (67616.4 pg/mL; detection limit 50 pg/mL) and no IgG (week 5-6), but when lymphoid-like cells were present (week 14-18) produced more IgM (4336295 ng/mL) and IgG (6.662.9 ng/mL) 
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( Figure 3C ). Thus, lymphoid-type cells from mesothelial cultures resemble phenotypically B1 cells in mice (CD19
) (29, (36) (37) (38) and humans (39) (40) (41) (42) . In the mouse, B1 cells represent the main Bcell population in the peritoneal and pleural cavities (41, 43) . In humans, B1 cells were reported in cord blood and adult peripheral blood (32, 42) . Thus, human mesothelial cell cultures can generate "B1-type" cells through a newly identified process of "mesothelial-to-lymphoid transition" (MLT).
Outgrowth of KSHV
1 /EBV 2 and KSHV 2 /EBV 1 Cell Lines
Mesothelial cultures from patient 81 (subject with PEL, KS, and KICS) and patient 90 (subject with KS and KICS but not PEL) differed because they generated lymphoid-type cells that did not die, instead displaying sustained growth. Culture 81 produced lymphoid cells from two wells (named 81a and 81b), culture 90 from one well only. The outgrowing cells were lymphoblast-like ( Figure 4A ) and produced lymphoid cell-rich ascites with or without associated solid tumors when injected intraperitoneally in three of three NOD/SCID mice (20) .
Lysates from the 81a and 81b lines were LANA1 Confirming this, a proportion of 81a and 81b cells displayed the typical speckled nuclear LANA1 staining, whereas a proportion of the 90 cells displayed nuclear EBNA2 staining (Supplementary Figure 3 , available online). qPCR ( Figure 4C ) showed that the 81a and 81b lines express the open reading frame (ORF) 73/LANA and several other latency KSHV genes (44) (45) (46) , the lytic cycle inducer ORF50/Rta (47) , and the lytic transcript ORF26 (48) . Line 90 expressed none of the KSHV-coded genes tested ( Figure 4C ), expressing instead the EBV latency genes EBNA-1, EBNA-2, LMP-1, LMP-2, and the immediate-early gene BZLF-1 ( Figure 4D ). The mesothelia (meso) from patients 81 and 90 did not express the KSHV-and EBV-coded genes By flow cytometry ( Figure 4E ), the 81a and 81b lines displayed an "indeterminate" phenotype typical of PEL (49, 50) , whereas the 90 line displayed a mature B-cell phenotype.
Thus, surface markers distinguish the 81a and 81b lines from the 90 line, each line sharing some of the markers of "B1-like" cells.
Analysis of clonality based on immunoglobulin (IGH and IGK loci) gene rearrangement (16, 51) revealed that the mesothelial culture-derived lines are clonal ( Figure 4F ). The pattern of K light chain restriction of the 81b line differed from that found in the primary PEL cells from the patient's 81 effusion, indicating that this line was not an outgrowth of the original PEL ( Figure 4F ). However, the K light chain restriction in the 81a line was not distinguishable from the original PEL. The clonal population detected in the EBV þ 90 line was not evident within the polyclonal primary cells from the effusion of patient 90 ( Figure 4F ). 
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Immunoglobulin (Ig) heavy chain (IGH) sequencing showed that the 90 and 81b lines display productively rearranged IGH sequences (IGHV4 and IGHV1 families, respectively) containing numerous point mutations. We did not detect a productively rearranged IGH sequence in the 81a cell line. However, 81a displays a productive rearrangement of the light chain (IGKV2) containing no mutations.
KSHV and EBV Can Infect Mesothelial Cells
Immunoblotting and qPCR did not show that the mesothelia from patients 81 and 90 were infected with KSHV or EBV during culture. However, immunofluorescence staining revealed rare KSHV (LANA-1) and EBV (LMP-2A) infection in mesothelia 81 and 90 more than four weeks prior to the emergence of the KSHV þ 81a and 81b and the EBV þ 90 cell lines ( Figure 5A ). The frequency of LANA þ and EBV þ cells was low in mesothelium 81
and 90 (estimated at $1:5000 for LANA and at $1:8000 for LMP2A). Only one cell had evidence of EBV and KSHV coinfection in mesothelium 81 ( Figure 5B ). Rare KSHV þ or EBV Based on these observations, we propose that occasional mesothelial cells within mesothelia that line body cavities of KSHV and/or EBV-infected individuals become naturally infected with KSHV, EBV, and infrequently both viruses ( Figure 6 ). In the presence of activating signals (21) , some mesothelial cells undergo mesothelial-to-lymphoid transition (MLT), resulting in the generation of B1-type lymphoid cells. When this process involves a KSHV and/or EBV-infected mesothelial cell, the resulting B1-type cell can be KSHV-infected, EBV-infected, or KSHVþEBV co-infected. Because these viruses can establish long-term latency in B-lineage cells and have oncogenic properties, the KSHV/EBV-infected B1-type cells acquire new capabilities, including responsiveness to mesothelium-derived cytokines and other factors, which prevents the rapid death typically observed in noninfected B1-type cells and leads to development of PEL or PEL-like tumors. Immunofluorescence detection of KSHV-latency-associated nuclear antigen (LANA)-1 (green or red) and EBV-latent membrane protein-2A (green); nuclear DAPI: blue. LANA ¼ latency-associated nuclear antigen; LMP ¼ latent membrane protein.
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Discussion
The current study provides a novel and unifying insight into PEL and PEL-like lymphomagenesis. We made three observations. First, we discovered that mesothelial cell monolayers undergo a mesothelial-to-lymphoid transition, resulting in the emergence of lymphoid-type cells. This discovery extends the spectrum of mesothelial functional capabilities beyond secretion of lubricants, maintenance of surface integrity, and ability to repair (53) . MLT resembles the emergence of hematopoietic cells from the endothelium of the yolk sac and the dorsal aorta identified as "endothelial-to-hematopoietic" transition (EHT) (54) (55) (56) . Endothelial and mesothelial cells can undergo phenotypic and functional change through "endothelial-to-mesenchymal" (EMT) and "mesothelial-to-mesenchymal" transitions (MMT) (13, 22, 53, 57, 58) . MLT, described here, may simply reflect an additional feature of mesothelial plasticity occurring in vitro when mesothelial cells senesce. Mesothelial cell senescence is not an artifact of culture as it also occurs physiologically in vivo and is accelerated by stress signals (23) .
The second discovery we made is that the lymphocytes emerging from mesothelial cultures have a B1-like phenotype, supporting a mesothelial origin of human B1-type cells. B1 lymphocytes are the main B-cell population in murine body cavities but are rare elsewhere (29, 43) . Human B1-like lymphocytes have been identified in cord and peripheral blood, but to our knowledge not in body cavities (35, 42, 59, 60) . Despite their importance in immune defense (41) , the origin of B1-type cells is unclear. During mouse development, B1 lymphocytes are first detected at embryonic day (E) 8.0-8.5 in the para-aortic mesoderm prior to the emergence of hematopoietic stem cells (HSCs) from the dorsal aorta (41, 61) , suggesting an HSCindependent origin of B1 cells (38, 62, 63) . All mesothelia that line body cavities derive from the para-aortic splanchnopleural mesoderm. Thus, B1-type cells and mesothelia have a common developmental derivation, raising the possibility that persistence of mesodermal precursors within adult mesothelia (64) confers B1-cell differentiation potential to these mesothelia.
The third observation we made is that mesothelial cells can be infected by KSHV and EBV, a finding consistent with our previous detection of LANA1 ARTICLE mesothelial cultures is a source of PEL-like lymphoma. From this perspective, body cavity-associated PEL and "PEL-like" malignancies would have a common mesothelial derivation. There are several limitations of this study. First, the mechanisms responsible for KSHV and EBV infection of mesothelial cells lining the body cavities are not known. Second, the endogenous signals that promote MLT in mesothelial cells are not fully identified. Third, the mechanisms that underlie KSHV immortalization of mesothelium-derived lymphoid cells need to be further explored. 
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